Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome

Leukemia Research

Volumn 34, Issue 1, 2010, Pages

  Ueda, Koki ^a   Nagai, Sumimasa ^a   Miyashita, Shin ich ^b   Kaise, Toshikazu ^b   Ichikawa, Motoshi ^a   Kumano, Keiki ^c   Hangaishi, Akira ^a   Nannya, Yasuhito ^a   Kurokawa, Mineo ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; C REACTIVE PROTEIN; METHYLPREDNISOLONE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEVER; HEART VENTRICLE FAILURE; HUMAN; HYPOTENSION; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MASS SPECTROMETRY; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BLOOD LEVEL; QT PROLONGATION; RECURRENT CANCER; RETINOIC ACID SYNDROME; SINUS TACHYCARDIA; THORAX PAIN; TREATMENT WITHDRAWAL;

ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; OXIDES; PERICARDIAL EFFUSION; PLEURAL EFFUSION;

EID: 73249119944     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.016     Document Type: Letter

References (11)

1. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
2. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 (2001) 3852-3860
3. Camacho L.H., Soignet S.L., Chanel S., et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18 (2000) 2620-2625
4. Unnikrishnan D., Dutcher J.P., Garl S., Varshneya N., Lucariello R., and Wiernik P.H. Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 124 (2004) 610-617
5. Fenaux P., Chastang C., Chevret S., et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukaemia. The European APL Group. Blood 94 (1999) 1192-1200
6. Yoshino Y., Yuan B., Miyashita S.I., et al. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 393 (2009) 689-697
7. Au W.Y., Tam S., and Kwong Y.L. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. Leuk Res 32 (2008) 357-358
8. States J.C., Srivastava S., Chen Y., and Barchowsky A. Arsenic and cardiovascular disease. Toxicol Sci 107 (2009) 312-323
9. Vizzardi E., Zanini G., Antonioli E., D'Aloia A., Raddino R., and Cas L.D. QT prolongation: a case of arsenical pericardial and pleural effusion. Cardiovasc Toxicol 8 (2008) 41-44
10. 3 in rabbits: evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration. Toxicol Appl Pharmacol 189 (2003) 214-220
11. Drolet B., Simard C., and Roden D.M. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109 (2004) 26-29